In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster ...

The bank's head of blockchain solutions Philippe Meyer told the DigiAssets conference in London that it started advising on ...